Cancer Screening Programs in Old Age

tibbi onkoloji ozel 13-4 kapak

Tarık SALMANa, Özlem ÖZDEMİRb

aİzmir Kâtip Çelebi Üniversitesi Atatürk Eğitim ve Araştırma Hastanesi, Tıbbi Onkoloji Kliniği, İzmir, TÜRKİYE
bİzmir Bozyaka Eğitim ve Araştırma Hastanesi, Tıbbi Onkoloji Kliniği, İzmir, TÜRKİYE

ABSTRACT
The average age of the world population increased as a result of the decrease in mortality rate which is correlated with the development of preventive health care services. One of the major health problems caused by the increase of the elderly population is chronic diseases. One of the most important preventive strategies for health problems in elderly individuals is the routine screening for early diagnosis. The incidence and prevalence of the disease should be evaluated according to the age because the screening tests used for early diagnosis show differences in frequency of disease between elderly and young population .Cardiovascular system diseases, bone metabolism diseases, cognitive dysfunctions, nutritional problems and cancer are the leading diseases for which screening is recommended in the elderly population. Another important topic is the question of when and how the screening tests should be applied, to which section of the society and which age group should be applied and at what point it should be terminated. In the context of community screening rules, when performing screening tests to elderly adults life expectancy, their ability to pass screening tests, and personal preferences should be taken into the consideration. In this article, we reviewed the evidence and guidelines for breast, colorectal, lung and prostate cancer applied to older adults.
Keywords: Elderly; early diagnosis of cancer; screening

Referanslar

  1. Alan Ö, Gürsel Ö, Ünsal M, Altın S, Kılçıksız S. Oncologic Approach in Geriatric Patients. Okmeydanı Tıp Dergisi. 2013;29:94-8 [Crossref]
  2. Clarfield AM. Screening in frail older people: An ounce of prevention or a pound of trouble? J Am Geriatr Soc. 2010;58(10):2016-21. [Crossref]  [PubMed]
  3. Walter LC, Covinsky KE. Cancer screening in elderly patients: a framework for individualized decision making. Jama. 2001; 285(21):2750- 6. [Crossref]  [PubMed]
  4. AGSCW. American Geriatrics Society identifies another five things that healthcare providers and patients should question. J Am Geriatr. Soc. 2014; 62(5):950-60. [Crossref]  [PubMed]
  5. Walter LC, Lewis CL, Barton MB. Screening for colorectal, breast, and cervical cancer in the elderly: a review of the evidence. The American journal of medicine. 2005; 118(10): 1078-86. [Crossref]  [PubMed]
  6. Schonberg MA, Davis RB, McCarthy EP, Marcantonio ER. External Validation of an Index to Predict Up to 9-Year Mortality of Community-Dwelling Adults Aged 65 and Older. Journal of the American Geriatrics Society. 2011; 59(8):1444-51. [Crossref]  [PubMed]  [PMC]
  7. Schonberg MA, Davis RB, McCarthy EP, Marcantonio ER. Index to predict 5-year mortality of community-dwelling adults aged 65 and older using data from the National Health Interview Survey. Journal of general internal medicine. 2009; 24(10):1115-22. [Crossref]  [PubMed]  [PMC]
  8. Lee SJ, Lindquist K, Segal MR, Covinsky KE. Development and validation of a prognostic index for 4-year mortality in older adults. Jama. 2006; 295(7):801-8. [Crossref]  [PubMed]
  9. Lee SJ, Leipzig RM, Walter LC. Incorporating lag time to benefit into prevention decisions for older adults. Jama. 2013; 310(24):2609-10. [Crossref]  [PubMed]  [PMC]
  10. Ashwin A. Kotwal, MD, MS1 and Mara A. Schonberg, MD, MPH , Cancer Screening in the Elderly: A Review of Breast, Colorectal, Lung, and Prostate Cancer Screening, Cancer J. Author manuscript; available in PMC 2018 Jul 1.
  11. Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87-108. 3. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7-30. [Crossref]  [PubMed]
  12. Welch HG, Prorok PC, O'Malley AJ, Kramer BS. Breast-Cancer Tumor Size, Overdiagnosis, and Mammography Screening Effectiveness. N Engl J Med 2016; 375:1438. [Crossref]  [PubMed]
  13. Bleyer A, Welch HG. Effect of three decades of screening mammography on breast-cancer incidence. N Engl J Med 2012; 367:1998.Autier P, Boniol M, Gavin A, Vatten LJ. Breast cancer mortality in neighbouring European countries database. BMJ 2011; 343:d4411. [Crossref]  [PubMed]  [PMC]
  14. Harris R, Yeatts J, Kinsinger L. Breast cancer screening for women ages 50 to 69 years a systematic review of observational evidence. Prev Med 2011; 53:108. [Crossref]  [PubMed]
  15. Kerlikowske K, Grady D, Barclay J, Sickles EA, Ernster V. Effect of age, breast density, and family history on the sen- sitivity of first screening mammography [comments]. JA- MA 1996;276(1):33-8 [Crossref]  [PubMed]
  16. Breast Cancer: Screening. Yayın tarihi: Kasım 2009. Erişim tarihi: 15.04.215. Erişim: [Link]
  17. Sağlık Bakanlığı, Meme Kanseri Tarama Programı Ulusal Standartları, URL: Erişim Tarihi:16.09.2015 [Erişim Tarihi: 02.01.2016] [Link]
  18. Siegel RL, Miller KD, Jemal A Cancer J Clin. 2019;69(1):7. [Crossref]  [PubMed]
  19. Whitlock EP, Lin JS, Liles E, Beil TL, Fu R. Screening for colorectal cancer: a targeted, updated systematic review for the US Preventive Services Task Force. Annals of internal medicine. 2008;149(9):638-58. [Crossref]  [PubMed]
  20. Bacchus CM, Dunfield L, Gorber SC, Holmes NM, Birtwhistle R, Dickinson JA, Lewin G, Singh H, Klarenbach S, Mai V, Tonelli M Recommendations on screening for colorectal cancer in primary care.Canadian Task Force on Preventive Health Care, CMAJ. 2016;188 (5):340.
  21. Lansdorp-Vogelaar I, von Karsa L European guidelines for quality assurance in colorectal cancer screening and diagnosis. First Edition- -Introduction., International Agency for Research on Cancer Endoscopy. 2012;44 (3):SE15. [Crossref]  [PubMed]
  22. (Accessed on November 23, 2016). [Link]
  23. Wilt TJ, Harris RP, Qaseem A,Screening for cancer: advice for high-value care from the American College of Physicians. High Value Care Task Force of the American College of Physicians Ann Intern Med. 2015;162(10): 718. [Crossref]  [PubMed]
  24. Bibbins-Domingo K, Grossman DC, Curry SJ, Davidson KW, Epling JW Jr, García FA,et al. Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement.US Preventive Services Task Force, 2016;315(23):2564-75. [Crossref]  [PubMed]
  25. Colorectal cancer screening for average‐risk adults: 2018 guideline update from the American Cancer Society (Accessed on May 30, 2018). [Link]
  26. American Cancer Society Recommendations for CRC Early Detecton, People at average risk (Accessed on June 14, 2017). [Link]
  27. Peterse EFP, Meester RGS, Siegel RL, Chen JC, Dwyer A, Ahnen DJ, Smith RA, Zauber AG, Lansdorp-Vogelaar The impact of the rising colorectal cancer incidence in young adults on the optimal age to start screening: Microsimulation analysis I to inform the American Cancer Society colorectal cancer screening guideline. Cancer. 2018;124(14): 2964. [Crossref]  [PubMed]  [PMC]
  28. European guidelines for quality assurance in colorectal cancer screening and diagnosis. First Edition-Introduction.Lansdorp-Vogelaar I, von Karsa L, International Agency for Research on Cancer Endoscopy. 2012;44(3): SE15. [Crossref]  [PubMed]
  29. (Accessed on November 23, 2016). [Link]
  30. Sağlık Bakanlığı, Kanserle Savaş Dairesi Başkanlığı 2006- 2008 yılları Türkiye Kanser İnsidansı, URL: [Erişim Tarihi:15.09.2015] [Link]
  31. ACOG Committee. Colonoscopy and colorectal cancer screening and prevention. Obstet Gynecol. 2007;110:1199-202. [Crossref]  [PubMed]
  32. Katz D, Elmore J, Wild D, Lucan S. Jekel's Epidemiology, Biostatistics. Preventive Medicine, and Public Health 4th Philadelphia, PA: Elsevier Saunders. 2014;217-26.
  33. ACS. [Accessed January 27, 2017] Estimated New Cases for the Four Major Cancers by Sex and Age Group, 2016. 2016. [Link]
  34. Humphrey LL, Deffebach M, Pappas M, et al. Screening for lung cancer with low-dose computed tomography: a systematic review to update the US Preventive services task force recommendation. Annals of internal medicine. 2013; 159(6):411-20. [Crossref]  [PubMed]
  35. CDC. Centers of Disease Control and Prevention. Current cigarette smoking among adults-United States, 2011. MMWR. Morbidity and mortality weekly report. 2012;61(44): 889.
  36. Prorok PC, Andriole GL, Bresalier RS, et al. Design of the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial. Controlled clinical trials. 2000; 21(6):273S- 309S. [Crossref]  [PubMed]
  37. Oken MM, Hocking WG, Kvale PA, et al. Screening by chest radiograph and lung cancer mortality: the Prostate, Lung, Colorectal, and Ovarian (PLCO) randomized trial. Jama. 2011;306(17):1865-73. [Crossref]  [PubMed]
  38. Pinsky PF, Church TR, Izmirlian G, Kramer BS. The National Lung Screening Trial: results stratified by demographics, smoking history, and lung cancer histology. Cancer. 2013; 119(22):3976-83. [Crossref]  [PubMed]  [PMC]
  39. Aberle D, Adams A, Berg C, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. The New England journal of medicine. 2011;365(5):395-409. [Crossref]  [PubMed]  [PMC]
  40. Moyer VA. Screening for lung cancer: US Preventive Services Task Force recommendation statement. Annals of internal medicine. 2014; 160(5):330-8. [Crossref]  [PubMed]
  41. Wender R, Fontham ET, Barrera E Jr, et al. American Cancer Society lung cancer screening guidelines. CA Cancer J Clin. 2013;63 (2):107-117. [Crossref]  [PubMed]  [PMC]
  42. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA: a cancer journal for clinicians. 2016; 66(1):7-30. [Crossref]  [PubMed]
  43. USPSTF. [Accessed 4-27-2017] Prostate Cancer Screening Draft Recommendations. 2017. [Link]
  44. Wolf A, Wender RC, Etzioni RB, et al. American Cancer Society guideline for the early detection of prostate cancer: update 2010. CA: a cancer journal for clinicians. 2010; 60(2):70- 98. [Crossref]  [PubMed]
  45. Carter HB. American Urological Association (AUA) guideline on prostate cancer detection: process and rationale. BJU international. 2013;112(5):543-7. [Crossref]  [PubMed]
  46. Brawer MK. Prostate-specific antigen: Current status. CA: a cancer journal for clinicians. 1999; 49(5):264-281. [Crossref]  [PubMed]